You are here: Home » Opinion » Editorial » Editorials
Thoughts on banking in the new decade
A dead end
Business Standard

Next step on vaccines

Nationwide roll-out needs meticulous planning

Topics
Coronavirus Vaccine | Coronavirus | Serum Institute of India

Business Standard Editorial Comment  |  New Delhi 



The expert committee nominated by the Central Drugs Standard Control Organisation (CDSCO) has recommended the use of the Oxford University/ vaccine AZD1222 for emergency use in this country. Given AstraZeneca’s decision to license the vaccine to Pune-based (SII), this shot will be a primary component of the programme in India. Other vaccines in SII’s stable include the one developed by the US-based company Novavax, of which the Duke University Global Health Innovation Centre reports it will produce one billion doses, alongside 500 million of AZD1222. Novavax began Phase III trials in the UK in November and has begun them in the US and Mexico in the past few days, and the Indian regulator has sought further information before permitting a bridging trial here that could speed up approval. Being behind on the timeline is problematic; as more and more trials are conducted alongside effective vaccines already being developed, the trials will slow as there are fewer volunteers available. Indeed, the other vaccine given permission for “restricted use in emergency situation in the public interest as an abundant precaution”, from Bharat Biotech, does not seem to have even completed its Phase III trials as yet. The logic of rushing ahead with this approval is, therefore, unclear, given no other regulator has seen the data, no trials elsewhere have been completed — and preparation to roll out the vaccine is itself running late.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Sun, January 03 2021. 22:41 IST

RECOMMENDED FOR YOU

.